A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

AML, selinexor, sorafenib, FLT3-mutation
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Outcome of patients with mutation of the FLT3 tyrosine kinase domain (FLT3-TKD) in acute myeloid leukemia (AML) remains controversial. Herein we present a retrospective study of 126 newly diagnosed AML patients performed in two French centers. FLT3-TKD mutations represented 12.7% of patients, while FLT3-internal tandem duplication (ITD) mutation was observed in 20.6% of AML cases and 1.6% of patients harbored both anomalies. At diagnosis, FLT3-TKD and FLT3-ITD were associated with higher peripheral leukocytes count and a higher blast count in bone marrow (P
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Significance of FLT3-ITD mutation in AML prognosis has been well established. The aim of this study was to investigate the prognostic impact of the FLT3 protein (CD135) expression, its association with FLT3-ITD mutation and to identify its role in minimal residual disease (MRD).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
In a large study focusing on the impact of CD135 on clincal presentation and its relation to other prognostic parameters, we addressed whether CD135 could be predictor of FMS-like tyrosine kinase 3 (FLT3) mutation. We found an association between CD135 expression and persistence of positive minimal residual disease postinduction status. CD135 is a crucial indicator of unfavorable outcome that influences complete remission status, disease-free survival, and overall survival in adult Egyptian acute myeloid leukeia patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Outcomes in acute myeloid leukemia (AML) have been correlated with predictive and prognostic factors including age, performance status, comorbidities, cytogenetics, and molecular mutations. Retrospective review of 137 adult AML patients identified 3+7 (3 days of anthracycline and 7 days of cytarabine) induction and absence of monosomal karyotype to positively predict complete remission whereas positive predictors of overall survival were younger age and the absence of monosomal karyotype.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Outcomes in acute myeloid leukemia (AML) have been correlated with predictive and prognostic factors including age, performance status, comorbidities, cytogenetics and molecular mutations. Retrospective review of 137 adult AML patients identified 3+7 induction and absence of monosomal karyotype to positively predict complete remission while positive predictors of overall survival were younger age and the absence of monosomal karyotype.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Acute myeloid leukemia (AML) is the second most common leukemia among adults. Although the median age at diagnosis is 67 years, with approximately one-third of patients aged 75 years or older, limited treatment options exist for the elderly, who have 5-year survival rates of only 5%. A systematic review was conducted to examine effectiveness and safety outcomes of treatment regimens in elderly ( ≥60 years old) patients with AML.Published literature on the topic was scant, and the review included only 22 articles examining outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Abstract BACKGROUND: Limited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer (NK)/T-cell neoplasms in the United States. PATIENTS AND METHODS: We performed a retrospective study of patients with NK/T-cell neoplasms diagnosed from 2001 to 2014 using the Surveillance, Epidemiology, and End Results program database. The Kaplan-Meier method was used to estimate the overall survival difference among the subgroups. Multivariate analyses were used to determine the factors affecting survival. RESULTS: For the 797 patients with NK/T-cell lymphoma, nasal type...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
We performed a retrospective population-based study to determine the epidemiology of natural killer (NK)/T-cell neoplasms in the United States. We found that the incidence of NK/T-cell lymphoma doubled during the past decade and is more common in Hispanic population. Unlike NK/T-cell lymphoma, no significant racial disparities were found in NK/T-cell leukemia. The risk of second primary acute myeloid leukemia might be increased for patients with NK/T-cell lymphoma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This was a retrospective population-based study aimed to determine the epidemiology of NK/T-cell neoplasms in the United States. We noticed that the incidence of NK/T-cell lymphoma doubled over the past decade and is more common in Hispanic population. Unlike NK/T-cell lymphoma, no significant racial disparities exist in NK/T-cell leukemia. There may be an increased risk of second primary acute myeloid leukemia (AML) in patients with NK/T-cell lymphoma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
This report adds to the pool of cases that reveal associations between use of lenalidomide and increased risk of developing secondary primary high-grade astrocytomas in multiple myeloma. PMID: 29616908 [PubMed - in process]
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Lymphoma | Myeloma | Study